Secondary membranous nephropathy associated to autoimmune polyglandular syndrome Type II

Alexa GolbusDepartment of Medicine, Medical University of South Carolina, Charleston, SC, USAView further author information

Krunal PatelDepartment of Medicine, Medical University of South Carolina, Charleston, SC, USAView further author information

Natalie FreidinDepartment of Medicine, Medical University of South Carolina, Charleston, SC, USACorrespondence[email protected]
View further author information

References

Gu Y, Xu H, Tang D. Mechanism of primary membranous nephropathy. Biomolecules. 2021;11:1. 2021 doi: 10.3390/biom11040513.
Web of Science ®Google Scholar
Sasaki K, Yasuda K, Nakanishi K, et al. Membranous nephropathy secondary to graves’ disease with deposits of thyroid peroxidase in an adult. CEN Case Rep. 2014;3(1):90–3. doi: 10.1007/s13730-013-0093-y.
PubMedGoogle Scholar
Sethi S. New antigens in membranous nephropathy. J Am Soc Nephrol. 2021;32(2):268–278. doi: 10.1681/ASN.2020071082.
PubMed Web of Science ®Google Scholar
Trujillo H, Alonso M, Praga M. New ways of understanding membranous nephropathy. Nephron. 2020;144(6):261–271. doi: 10.1159/000506948.
PubMed Web of Science ®Google Scholar
Kahaly GJ, Frommer L. Polyglandular autoimmune syndromes. J Endocrinol Invest. 2018;41(1):91–98. doi: 10.1007/s40618-017-0740-9.
PubMed Web of Science ®Google Scholar
de Menezes Neves PDM, Rego Muniz MP, Morgantetti GF, et al. Membranous nephropathy secondary to graves’ disease: a case report. Front Immunol. 2022;13:824124. doi: 10.3389/fimmu.2022.824124.
PubMed Web of Science ®Google Scholar